Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | CACNB4 | O00305 | 3/20 | 0.48 |
| ▸ | CACNA1A | O00555 | 3/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.48 |
| ▸ | CACNG3 | O60359 | 3/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325758 | 0.76 | SMN1; SMN2 (0.77) | ALDH1A1LMNASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL18595384 | 0.71 | TDP1 (0.50) | ALDH1A1LMNASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL31115728 | 0.70 | RAB9A (0.55) | CYP1A2CYP2C9ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11088624 | 0.70 | KMT2A (0.53) | ALDH1A1LMNASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL3000994 | 0.70 | SMN1; SMN2 (0.52) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL20154172 | 0.70 | ADORA3 (0.53) | ALDH1A1LMNASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL7980956 | 0.70 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL30640218 | 0.69 | SMN1; SMN2 (0.53) | CYP1A2CYP2C9ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL26091779 | 0.69 | SMN1; SMN2 (0.53) | CYP1A2CYP2C9ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15976546 | 0.69 | ALDH1A1 (1.00) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CYP1A2 74/4885CYP2C9 168/4885CYP2C19 95/4885 |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CYP1A2 74/4885CYP2C9 168/4885CYP2C19 95/4885 |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CYP1A2 74/4885CYP2C9 168/4885CYP2C19 95/4885 |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CYP1A2 74/4885CYP2C9 168/4885CYP2C19 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.